ATE285252T1 - Mittel zur verhinderung der truebung der vorderen linsenkapsel - Google Patents

Mittel zur verhinderung der truebung der vorderen linsenkapsel

Info

Publication number
ATE285252T1
ATE285252T1 AT96914498T AT96914498T ATE285252T1 AT E285252 T1 ATE285252 T1 AT E285252T1 AT 96914498 T AT96914498 T AT 96914498T AT 96914498 T AT96914498 T AT 96914498T AT E285252 T1 ATE285252 T1 AT E285252T1
Authority
AT
Austria
Prior art keywords
agent
lens capsule
anterior lens
preventing
opacity
Prior art date
Application number
AT96914498T
Other languages
English (en)
Inventor
Katarina Edsman
Carl-Gustaf Goelander
Kerstin Wickstroem
Original Assignee
Pfizer Health Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Health Ab filed Critical Pfizer Health Ab
Application granted granted Critical
Publication of ATE285252T1 publication Critical patent/ATE285252T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • A61K9/0051Ocular inserts, ocular implants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/12Ophthalmic agents for cataracts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
AT96914498T 1995-05-05 1996-05-03 Mittel zur verhinderung der truebung der vorderen linsenkapsel ATE285252T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9501671A SE9501671D0 (sv) 1995-05-05 1995-05-05 Method and composition for prevention of posterior capsule opacification
PCT/SE1996/000588 WO1996034629A1 (en) 1995-05-05 1996-05-03 Method and composition for prevention of posterior capsule opacification

Publications (1)

Publication Number Publication Date
ATE285252T1 true ATE285252T1 (de) 2005-01-15

Family

ID=20398207

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96914498T ATE285252T1 (de) 1995-05-05 1996-05-03 Mittel zur verhinderung der truebung der vorderen linsenkapsel

Country Status (7)

Country Link
EP (1) EP0825877B1 (de)
JP (1) JPH11504342A (de)
AT (1) ATE285252T1 (de)
AU (1) AU5784096A (de)
DE (1) DE69634080T2 (de)
SE (1) SE9501671D0 (de)
WO (1) WO1996034629A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6491721B2 (en) 1998-04-15 2002-12-10 Alcon Manufacturing, Ltd. Toric intraocular lens material
ATE206314T1 (de) 1998-04-15 2001-10-15 Alcon Lab Inc Beschichtungszusammensetzung für intraocularen linsen
US6455318B1 (en) 1998-04-15 2002-09-24 Alcon Manufacturing, Ltd. Collagen IV adhesion assay for intraocular lens materials
US6482230B1 (en) 1998-04-15 2002-11-19 Alcon Manufacturing, Ltd. Lens epithelial cell growth assay for intraocular lens materials
CA2317757C (en) * 1998-04-15 2008-03-25 Alcon Laboratories, Inc. Bicomposite intraocular lens and method for its preparation
SE0402272D0 (sv) 2004-09-21 2004-09-21 Amo Groningen Bv Methods of treating a body site with a viscoelastic preparation
EP1791523B1 (de) * 2004-09-21 2013-10-23 AMO Groningen B.V. Methode zur herstellung einer viskoelastischen lösung
WO2014153394A1 (en) * 2013-03-21 2014-09-25 Genisphere, Llc Cellular delivery of dna intercalating agents
EP3416671A4 (de) 2016-02-19 2019-10-30 Genisphere, LLC Nukleinsäureträger und therapeutische verfahren zur verwendung

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2014244A1 (en) * 1989-04-13 1990-10-13 Takeda Chemical Industries, Ltd. Stabilized composition of anthracyclines

Also Published As

Publication number Publication date
JPH11504342A (ja) 1999-04-20
EP0825877A1 (de) 1998-03-04
SE9501671D0 (sv) 1995-05-05
EP0825877B1 (de) 2004-12-22
DE69634080D1 (de) 2005-01-27
WO1996034629A1 (en) 1996-11-07
AU5784096A (en) 1996-11-21
DE69634080T2 (de) 2006-03-02

Similar Documents

Publication Publication Date Title
UA29563C2 (uk) Мікрокапсула для тривалого вивільнення фізіологічно активного пептиду
NO178605C (no) Apparat for tilförsel av preparat med vedvarende avgivelse av et farmasöytisk middel til crevikularlommen for behandling av tannrotsykdom
HUP9802665A3 (en) Composition for controlled release of miotic and mydriatic drugs in the anterior chamber
ATE216241T1 (de) Sehr niedrigdosiertes orales kontrazeptiv mit weniger menstruationsblutungen und verzögerter wirkung
ATE198152T1 (de) Oral anzuwendende arzneizubereitung mit verzögerter wirkstoffabgabe
ATE220898T1 (de) Nifedipinzubereitung mit langanhaltender freisetzung
IL96900A0 (en) Pharmaceutical composition containing naproxen
YU13695A (sh) Upotreba 2-fenil-3-aroilbenzotiofena i njihove farmaceutske formulacije
BG104476A (en) Therapeutical form for tolterodin with controlled release
GR3036798T3 (en) Effervescent pharmaceutical formulations containing controlled release biodegradable microcapsules
GB9408775D0 (en) Use of certain methanebisphosphonic acid derivatives to prevent prothesis loosening and prothesis migration
MY130098A (en) Local drug delivery film for periodontal treatment
ATE285252T1 (de) Mittel zur verhinderung der truebung der vorderen linsenkapsel
ATE205704T1 (de) 5-asa enthaltendes orales arzneimittel mit modifizierter freisetzung sowie verfahren zur behandlung von darmerkrankungen
PL317996A1 (en) Carbamazepinic form of a drug with retarded release of biologically active substance
Feinberg Update on treatment of CMV retinitis
MY114610A (en) Controlled drug delivery system for diltiazem.
DE69629718D1 (de) Mittel zum halten von zahnprothesen
MX9605327A (es) Uso de ciertos derivados de acido metanbisfosfonico para prevenir el aflojamiento de las protesis y la emigracion de las protesis.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties